Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
166 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Anthrax - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Anthrax - Pipeline Review, H1 2016', provides an overview of the Anthrax pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anthrax, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Anthrax - The report reviews pipeline therapeutics for Anthrax by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Anthrax therapeutics and enlists all their major and minor projects - The report assesses Anthrax therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Anthrax Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Anthrax - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Anthrax pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Anthrax Overview 8 Therapeutics Development 9 Pipeline Products for Anthrax - Overview 9 Pipeline Products for Anthrax - Comparative Analysis 10 Anthrax - Therapeutics under Development by Companies 11 Anthrax - Therapeutics under Investigation by Universities/Institutes 13 Anthrax - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Anthrax - Products under Development by Companies 17 Anthrax - Products under Investigation by Universities/Institutes 20 Anthrax - Companies Involved in Therapeutics Development 21 Aduro BioTech, Inc. 21 Altimmune, Inc. 22 Aphios Corporation 23 Aradigm Corporation 24 AtralCipan 25 Cellceutix Corporation 26 ContraFect Corporation 27 Dynavax Technologies Corporation 28 Elusys Therapeutics, Inc. 29 Emergent BioSolutions Inc. 30 GlaxoSmithKline Plc 31 Green Cross Corporation 32 Grifols, S.A. 33 Hawaii Biotech, Inc. 34 iBio, Inc. 35 Merck & Co., Inc. 36 Microbiotix, Inc. 37 NanoBio Corporation 38 ONI BioPharma Inc. 39 PaxVax, Inc. 40 Pfenex Inc. 41 PharmAthene, Inc. 42 Protein Potential, LLC 43 ProThera Biologics, LLC. 44 Soligenix, Inc. 45 Syntiron LLC 46 Tetraphase Pharmaceuticals Inc. 47 United Therapeutics Corporation 48 VLP Biotech, Inc. 49 Anthrax - Therapeutics Assessment 50 Assessment by Monotherapy Products 50 Assessment by Combination Products 51 Assessment by Target 52 Assessment by Mechanism of Action 54 Assessment by Route of Administration 56 Assessment by Molecule Type 58 Drug Profiles 60 anthrax (virus like particles) vaccine - Drug Profile 60 anthrax + plague vaccine - Drug Profile 61 anthrax vaccine - Drug Profile 62 anthrax vaccine - Drug Profile 63 anthrax vaccine - Drug Profile 64 anthrax vaccine - Drug Profile 65 anthrax vaccine - Drug Profile 66 anthrax vaccine - Drug Profile 67 anthrax vaccine - Drug Profile 69 anthrax vaccine 2 - Drug Profile 70 anthrax vaccine next generation - Drug Profile 72 ARD-3100 - Drug Profile 73 AV-7909 - Drug Profile 75 CF-306 - Drug Profile 76 CF-307 - Drug Profile 77 CF-308 - Drug Profile 78 ciprofloxacin hydrochloride - Drug Profile 79 DPX-Anthrax - Drug Profile 80 DV-230 - Drug Profile 81 Epimerox - Drug Profile 82 GC-1109 - Drug Profile 83 GREANX - Drug Profile 84 Human Antibody Based Vaccines - Drug Profile 85 KKL-35 - Drug Profile 87 Marinus - Drug Profile 88 Monoclonal Antibody for Respiratory Anthrax - Drug Profile 89 Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax - Drug Profile 90 obiltoxaximab - Drug Profile 91 OG-253 - Drug Profile 93 PBI-220 - Drug Profile 95 Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile 97 PMX-0196 - Drug Profile 98 PMX-0243 - Drug Profile 99 PMX-225 - Drug Profile 100 PMX-231 - Drug Profile 101 PreviThrax - Drug Profile 102 Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile 104 Px-563L - Drug Profile 105 raxibacumab - Drug Profile 106 RC-100b - Drug Profile 107 RiVax + SGX-204 - Drug Profile 108 Second Generation Px-563L - Drug Profile 109 SGX-204 - Drug Profile 110 Small Molecule to Inhibit DNA Helicase for Infectious Diseases - Drug Profile 111 Small Molecule to Inhibit Enoyl-Reductase for Anthrax and Tularaemia - Drug Profile 112 Small Molecules for Anthrax - Drug Profile 113 Small Molecules for Bacterial Infections - Drug Profile 114 Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax - Drug Profile 115 Small Molecules to Inhibit Lethal Factor for Anthrax - Drug Profile 116 Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile 118 Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile 119 solithromycin - Drug Profile 120 TP-271 - Drug Profile 123 Anthrax - Recent Pipeline Updates 125 Anthrax - Dormant Projects 149 Anthrax - Discontinued Products 153 Anthrax - Product Development Milestones 154 Featured News & Press Releases 154 Appendix 161 Methodology 161 Coverage 161 Secondary Research 161 Primary Research 161 Expert Panel Validation 161 Contact Us 161 Disclaimer 162
List of Tables
Number of Products under Development for Anthrax, H1 2016 13 Number of Products under Development for Anthrax - Comparative Analysis, H1 2016 14 Number of Products under Development by Companies, H1 2016 15 Number of Products under Development by Companies, H1 2016 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H1 2016 17 Comparative Analysis by Late Stage Development, H1 2016 18 Comparative Analysis by Clinical Stage Development, H1 2016 19 Comparative Analysis by Early Stage Development, H1 2016 20 Products under Development by Companies, H1 2016 21 Products under Development by Companies, H1 2016 (Contd..1) 22 Products under Development by Companies, H1 2016 (Contd..2) 23 Products under Investigation by Universities/Institutes, H1 2016 24 Anthrax - Pipeline by Aduro BioTech, Inc., H1 2016 25 Anthrax - Pipeline by Altimmune, Inc., H1 2016 26 Anthrax - Pipeline by Aphios Corporation, H1 2016 27 Anthrax - Pipeline by Aradigm Corporation, H1 2016 28 Anthrax - Pipeline by AtralCipan, H1 2016 29 Anthrax - Pipeline by Cellceutix Corporation, H1 2016 30 Anthrax - Pipeline by ContraFect Corporation, H1 2016 31 Anthrax - Pipeline by Dynavax Technologies Corporation, H1 2016 32 Anthrax - Pipeline by Elusys Therapeutics, Inc., H1 2016 33 Anthrax - Pipeline by Emergent BioSolutions Inc., H1 2016 34 Anthrax - Pipeline by GlaxoSmithKline Plc, H1 2016 35 Anthrax - Pipeline by Green Cross Corporation, H1 2016 36 Anthrax - Pipeline by Grifols, S.A., H1 2016 37 Anthrax - Pipeline by Hawaii Biotech, Inc., H1 2016 38 Anthrax - Pipeline by iBio, Inc., H1 2016 39 Anthrax - Pipeline by Merck & Co., Inc., H1 2016 40 Anthrax - Pipeline by Microbiotix, Inc., H1 2016 41 Anthrax - Pipeline by NanoBio Corporation, H1 2016 42 Anthrax - Pipeline by ONI BioPharma Inc., H1 2016 43 Anthrax - Pipeline by PaxVax, Inc., H1 2016 44 Anthrax - Pipeline by Pfenex Inc., H1 2016 45 Anthrax - Pipeline by PharmAthene, Inc., H1 2016 46 Anthrax - Pipeline by Protein Potential, LLC, H1 2016 47 Anthrax - Pipeline by ProThera Biologics, LLC., H1 2016 48 Anthrax - Pipeline by Soligenix, Inc., H1 2016 49 Anthrax - Pipeline by Syntiron LLC, H1 2016 50 Anthrax - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2016 51 Anthrax - Pipeline by United Therapeutics Corporation, H1 2016 52 Anthrax - Pipeline by VLP Biotech, Inc., H1 2016 53 Assessment by Monotherapy Products, H1 2016 54 Assessment by Combination Products, H1 2016 55 Number of Products by Stage and Target, H1 2016 57 Number of Products by Stage and Mechanism of Action, H1 2016 59 Number of Products by Stage and Route of Administration, H1 2016 61 Number of Products by Stage and Molecule Type, H1 2016 63 Anthrax Therapeutics - Recent Pipeline Updates, H1 2016 129 Anthrax - Dormant Projects, H1 2016 153 Anthrax - Dormant Projects (Contd..1), H1 2016 154 Anthrax - Dormant Projects (Contd..2), H1 2016 155 Anthrax - Dormant Projects (Contd..3), H1 2016 156 Anthrax - Discontinued Products, H1 2016 157
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.